{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:51:34Z","timestamp":1787165494512,"version":"build-2736575974"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction and importance:<\/jats:title>\n                    <jats:p>Medulloblastoma (MBL) is the most common malignant brain tumor in children, accounting for up to 25% of primary central nervous system neoplasms. Standard treatment includes surgical resection, chemotherapy, and craniospinal irradiation (CSI). While these multimodal therapies have significantly improved survival, they are associated with long-term toxicities. One rare but serious complication is therapy-related acute myeloid leukemia (t-AML), which results from exposure to cytotoxic chemotherapy and\/or radiotherapy. t-AML is known for its poor prognosis, low treatment response, and increased toxicity, making it a particularly challenging outcome in pediatric oncology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation:<\/jats:title>\n                    <jats:p>We present the case of a pediatric patient with medulloblastoma who experienced three disease relapses. During treatment with etoposide for recurrent medulloblastoma, the patient developed t-AML. Despite the typically poor outcomes associated with t-AML, the patient achieved remission from leukemia. However, medulloblastoma remained refractory.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical discussion:<\/jats:title>\n                    <jats:p>This case highlights the dual burden of disease recurrence and secondary malignancy in pediatric oncology patients. The development of t-AML following etoposide therapy raises important considerations about cumulative treatment-related risks. While remission of t-AML was successfully achieved, the ongoing progression of medulloblastoma underscores the complexity of managing patients with multiple, concurrent oncologic challenges. It also calls attention to the limitations of current therapeutic approaches in preventing and treating long-term complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The case underscores the importance of vigilant long-term follow-up and surveillance for hematologic abnormalities in medulloblastoma patients, especially those exposed to high-risk chemotherapeutic agents. Early detection and intervention for therapy-related complications like t-AML are essential to optimize care, even as the primary malignancy may continue to progress.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ms9.0000000000003650","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T14:00:24Z","timestamp":1754488824000},"page":"6729-6734","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Therapy-related acute myeloid leukemia following aggressive treatment for pediatric medulloblastoma: a case report of a 13-year-old and review of literature"],"prefix":"10.1097","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7732-1501","authenticated-orcid":false,"given":"Zeinab","family":"Karaki","sequence":"first","affiliation":[{"name":"Faculty of Medical Sciences, Lebanese University, Rafic Hariri University Campus, Beirut, Lebanon"},{"name":"MEDICA Research Investigation, Hadath, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Kotaich","sequence":"additional","affiliation":[{"name":"Faculty of Medical Sciences, Lebanese University, Rafic Hariri University Campus, Beirut, Lebanon"},{"name":"MEDICA Research Investigation, Hadath, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrystelle","family":"Chemaly","sequence":"additional","affiliation":[{"name":"Faculty of Medical Sciences, Lebanese University, Rafic Hariri University Campus, Beirut, Lebanon"},{"name":"MEDICA Research Investigation, Hadath, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mourad","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medical Sciences, Beirut Arab University, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3608-7124","authenticated-orcid":false,"given":"Rhaghida","family":"Dhayni","sequence":"additional","affiliation":[{"name":"Head of Pediatric Hematology-Oncology Unit, Hammoud Hospital University Medical Center (HHUMC), Saida, Lebanon"},{"name":"Residency Program Director, Hammoud Hospital University Medical Center (HHUMC), Saida, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"R1-20260204","doi-asserted-by":"crossref","first-page":"28\u201338","DOI":"10.14791\/btrt.2022.0046","article-title":"Medulloblastoma: current perspectives and recent advances","volume":"11","author":"Choi","year":"2023","journal-title":"Brain Tumor Res Treat"},{"key":"R2-20260204","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4103\/1793-5482.151516","article-title":"Medulloblastoma: a common pediatric tumor: prognostic factors and predictors of outcome","volume":"10","author":"Kumar","year":"2015","journal-title":"Asian J Neurosurg"},{"key":"R3-20260204","doi-asserted-by":"crossref","first-page":"e27410","DOI":"10.1002\/pbc.27410","article-title":"Therapy-related acute myeloid leukemia following treatment for cancer in childhood: a population-based registry study","volume":"65","author":"Brown","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"R4-20260204","doi-asserted-by":"crossref","first-page":"803\u201311","DOI":"10.1097\/MPH.0b013e3181ba43dc","article-title":"Pediatric therapy-related myelodysplastic syndrome\/acute myeloid leukemia: the MD Anderson cancer center experience","volume":"31","author":"Aguilera","year":"2009","journal-title":"J Pediatr Hematol Oncol"},{"key":"R5-20260204","doi-asserted-by":"crossref","first-page":"e27576","DOI":"10.1002\/pbc.27576","article-title":"Medulloblastoma and secondary acute myeloid leukemia in a patient with Turner syndrome","volume":"66","author":"Davidow","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"R6-20260204","doi-asserted-by":"crossref","first-page":"1364199","DOI":"10.3389\/fonc.2024.1364199","article-title":"Case report: therapy-related myeloid neoplasms in three pediatric cases with medulloblastoma","volume":"14","author":"Mak","year":"2024","journal-title":"Front Oncol"},{"key":"R7-20260204","doi-asserted-by":"crossref","first-page":"97\u2013103","DOI":"10.1093\/neuonc\/nos267","article-title":"Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children\u2019s oncology group trial A9961","volume":"15","author":"Packer","year":"2013","journal-title":"Neuro Oncol"},{"key":"R8-20260204","doi-asserted-by":"crossref","first-page":"249\u201360","DOI":"10.1159\/000336483","article-title":"Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience","volume":"82","author":"Zapletalova","year":"2012","journal-title":"Oncology"},{"key":"R9-20260204","doi-asserted-by":"crossref","first-page":"e29031","DOI":"10.1002\/pbc.29031","article-title":"Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: report of a COG randomized Phase II screening trial","volume":"68","author":"Levy","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"R10-20260204","doi-asserted-by":"crossref","first-page":"841\u201348","DOI":"10.1007\/s11910-023-01316-9","article-title":"Recent advances in pediatric medulloblastoma","volume":"23","author":"Jackson","year":"2023","journal-title":"Curr Neurol Neurosci Rep"},{"key":"R11-20260204","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3390\/cancers14030679","article-title":"The current landscape of targeted clinical trials in non-wnt\/non-shh medulloblastoma","volume":"14","author":"Ghasemi","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R12-20260204","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3390\/diagnostics12010061","article-title":"Subgroup-specific diagnostic, prognostic, and predictive markers influencing pediatric medulloblastoma treatment","volume":"12","author":"Ray","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"R13-20260204","doi-asserted-by":"crossref","first-page":"1\u20136","DOI":"10.1038\/s44276-024-00064-8","article-title":"New light on chemotherapy toxicity and its prevention","volume":"2","author":"Juthani","year":"2024","journal-title":"BJC Reports"},{"key":"R14-20260204","doi-asserted-by":"crossref","first-page":"101169","DOI":"10.1016\/j.tranon.2021.101169","article-title":"Etoposide, an anticancer drug involved in therapy-related secondary leukemia: enzymes at play","volume":"14","author":"Zhang","year":"2021","journal-title":"Transl Oncol"},{"key":"R15-20260204","doi-asserted-by":"crossref","first-page":"678\u201383","DOI":"10.1111\/iju.13597","article-title":"Therapy-related acute myeloid leukemia and myelodysplastic syndrome among refractory germ cell tumor patients","volume":"25","author":"Inoue","year":"2018","journal-title":"Int J Urol"},{"key":"R16-20260204","doi-asserted-by":"crossref","first-page":"539\u201344","DOI":"10.1007\/s00701-017-3454-z","article-title":"Image-guided Ommaya reservoir insertion for intraventricular chemotherapy: a retrospective series","volume":"160","author":"Lau","year":"2018","journal-title":"Acta Neurochir (Wien)"},{"key":"R17-20260204","doi-asserted-by":"crossref","first-page":"103607","DOI":"10.1016\/j.critrevonc.2022.103607","article-title":"Diagnosis and treatment of therapy-related acute myeloid leukemia","volume":"171","author":"Stephen","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"R18-20260204","doi-asserted-by":"crossref","first-page":"449\u201363","DOI":"10.1016\/j.hoc.2019.11.003","article-title":"secondary acute myeloid leukemia: a primary challenge of diagnosis and treatment","volume":"34","author":"Winer","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"key":"R19-20260204","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.3390\/cancers14205128","article-title":"Improved long-term survival of patients with recurrent medulloblastoma treated with a \u201cMEMMAT-like\u201d metronomic antiangiogenic approach","volume":"14","author":"Slavc","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R20-20260204","first-page":"13\u201323","article-title":"Clonal Hematopoiesis and therapy related MDS\/AML. Best practice & research","volume":"32","author":"Desai","year":"2019","journal-title":"Clin Hematol"},{"key":"R21-20260204","doi-asserted-by":"crossref","first-page":"2927\u201335","DOI":"10.1200\/JCO.2012.48.5052","article-title":"Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma","volume":"31","author":"Zhukova","year":"2013","journal-title":"J Clin Oncol"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000003650","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T15:03:14Z","timestamp":1770217394000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000003650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000003650","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"2025-05-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}